This study aims to develop a polymer-based nanovaccine to enhance cancer immunotherapy by overcoming challenges related to antigen degradation and tumor immunosuppression.
Developed G4P-C7A-R848, a polymer conjugate that self-assembles into nanoparticles.
Administered nanoparticles systemically to murine models to test efficacy in promoting tumor immunity.
Evaluated effects on dendritic cells, T cells, and macrophages in the tumor microenvironment.
PCR-NPs treatment led to significant tumor regression in multiple murine models.
Enhanced infiltration and activation of CD8+ T cells were observed.
Prolonged survival was noted in treated mice compared to controls.